[PP.17.04] BLOOD PRESSURE WAS ASSOCIATED WITH GLOMERULOMEGALY, INTERSTITIAL FIBROSIS AND RENAL PROGRESSION IN IGA NEPHROPATHY. (September 2017)

• Record Type: Journal Article
• Authors: Ihm, C.; Lee, T.; Jeong, K.; Kim, J.; Park, E.; Jung, S.; Ihm, H.
• Is Part Of: Journal of hypertension. Volume 35(2017)Supplement 2
• Publication Date: 2017-09
• Subjects: Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/01.hjh.0000523649.60023.45
• Languages: English
• ISSNs: 1473-5598

Abstract

Abstract : Objective: Several factors contribute to the development of hypertension in patients with IgA nephropathy (IgAN). This study was conducted to find the relationships between baseline blood pressure and clinico-pathological findings in patients with IgAN and normal renal function. Design and method: Clinico-pathological findings were analyzed in a total of 163 patients with IgAN and normal serum creatinine levles from The Kyung-Hee Cohort of Glomerulonephritis. The glomerular surface area (GSA) was determined in the renal biopsy specimen using imaging analysis software. The serum and urine angiotensinogen (AGT) concentrations were measured using human ELISA kits. Results: Systolic BP was >130 mmHg in 72 patients (44%) and >140 mmHg in 42 (26%). Systolic BP was positively correlated with age, serum uric acid concentrations, IgM deposit and baseline and follow-up proteinuria, and negatively with follow-up glomerular filtration rate and the slope of change in 1/serum creatinine for 2 years, while it has no significant relationships with serum and urine AGT and 24 hour urinary sodium excretion. Patients with systolic BP >130 mmHg as compared with those <130 mmHg showed higher GSA, severer degree of interstitial fibrosis, larger amount of proteinuria after follow-up, and higher serum creatinine and lower glomerular filtration rate after follow-up. Conclusions: Baseline systolic BP was associated with renal progression and severe pathological findings, glomerulomegaly and interstitial fibrosis, in patients with IgAN.